Clinical Trials
22 trialsNCT00003042 2026-02-20
Chemotherapy and Stem Cell Transplantation in Treating Patients With Stage IIIB Breast Cancer
City of Hope Medical Center
Phase 2 Completed
NCT02876302 2026-02-04
Study Of Ruxolitinib (INCB018424) With Preoperative Chemotherapy For Triple Negative Inflammatory Breast Cancer
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT02623972 2025-11-25
A Phase 2 Study of Eribulin Followed by AC as Preoperative Therapy for HER2-negative Inflammatory Breast Cancer
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT00295893 2025-09-25
Combination Chemotherapy With or Without Trastuzumab in Treating Patients With Stage II or Stage III Breast Cancer
City of Hope Medical Center
Phase 2 Active not recruiting
NCT03515798 2025-09-12
PELICAN
Institut Paoli-Calmettes
Phase 2 Active not recruiting
NCT05177796 2024-10-24
Panitumumab and Pembrolizumab in Combination With Neoadjuvant Chemotherapy for the Treatment of Stage III-IV Triple Negative Breast Cancer
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT01036087 2023-03-30
Panitumumab, Nab-paclitaxel and Carboplatin for HER2 Negative Inflammatory Breast Cancer
M.D. Anderson Cancer Center
Phase 2 Completed
NCT03012100 2023-01-13
Multi-epitope Folate Receptor Alpha Peptide Vaccine, GM-CSF, and Cyclophosphamide in Treating Patients With Triple Negative Breast Cancer
Academic and Community Cancer Research United
Phase 2 Active not recruiting
NCT00464646 2021-10-25
Therapy With Bevacizumab (BEV), Epirubicin, and Cyclophosphamide Followed by Docetaxel Plus Trastuzumab and BEV Given as Neoadjuvant or Adjuvant Therapy for Women With Locally Advanced HER2 Positive Invasive Breast Cancer
NSABP Foundation Inc
Phase 2 Completed
NCT02682693 2021-02-02
GeparX
GBG Forschungs GmbH
Phase 2 Completed
NCT00820547 2019-10-22
Beverly1
UNICANCER
Phase 2 Completed
NCT00513695 2019-08-07
Sunitinib Malate, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide Before Surgery in Treating Patients With Stage IIB-IIIC Breast Cancer
University of Washington
Phase 2 Completed
NCT00499122 2018-01-02
NOV-002, Doxorubicin, Cyclophosphamide, and Docetaxel in Women With Newly Diagnosed Stage II or IIIC Breast Cancer
University of Miami
Phase 2 Completed
NCT00006110 2017-07-31
NRR
UNC Lineberger Comprehensive Cancer Center
Phase 2 Completed
NCT00856492 2017-06-27
S0800, Nab-Paclitaxel, Doxorubicin, Cyclophosphamide, and Pegfilgrastim With or Without Bevacizumab in Treating Women With Inflammatory or Locally Advanced Breast Cancer
SWOG Cancer Research Network
Phase 2 Completed
NCT00182793 2017-02-23
Combination Chemotherapy With or Without Trastuzumab Followed By an Autologous Stem Cell Transplant and Radiation Therapy in Treating Patients With Stage III or Stage IV Breast Cancer
City of Hope Medical Center
Phase 2 Completed
NCT00756470 2014-11-17
Phase II Neoadjuvant in Inflammatory Breast Cancer
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT00049114 2013-06-06
Tipifarnib, Doxorubicin, and Cyclophosphamide in Treating Women With Locally Advanced Breast Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00072319 2013-03-04
Neoadjuvant or Adjuvant Epirubicin, Cyclophosphamide, and Paclitaxel in Treating Women With Stage I, Stage II, or Stage III Breast Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00005798 2012-10-26
CTC
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT01641406 2012-07-16
NACprotocol
Auxilio Mutuo Cancer Center
Phase 2 Unknown
NCT00398489 2010-11-09
Docetaxel, Epirubicin, and Cyclophosphamide With or Without Trastuzumab in Treating Women With Locally Advanced Breast Cancer That Can Be Removed By Surgery
National Cancer Institute (NCI)
Phase 2 Unknown